Trial Profile
A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary)
- Indications Leiomyosarcoma; Liposarcoma
- Focus Therapeutic Use
- Acronyms TRAVELL
- 07 Jun 2022 Primary endpoint has not been met. (Growth Modulation Rate), as per Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 18 Nov 2019 According to a PharmaMar media release, preliminary data from this trial were presneted at the at the International Congress of the Connective Tissue Oncological Society (CTOS).